Article info

Download PDFPDF

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

Authors

  1. Correspondence to Nadine L de Boer; n.deboer{at}erasmusmc.nl
View Full Text

Citation

de Boer NL, van Kooten JP, Burger JWA, et al
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

Publication history

  • Received September 19, 2018
  • Revised February 6, 2019
  • Accepted February 26, 2019
  • First published May 14, 2019.
Online issue publication 
May 14, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.